Specialty medical injectable drug program updates: Hemophilia Treatment Centers

Please review the following information to determine changes to our specialty medical injectable drug programs.

Beginning Aug. 1, 2021, Hemophilia Treatment Centers (HTCs) seeking coverage under a member’s medical benefit for self-administered medications, such as Hemlibra or factor products, used to treat bleeding disorders must be contracted with a specific HTC fee schedule that allows them to dispense bleeding disorder medications for UnitedHealthcare Commercial members.  HTCs not contracted with an HTC-specific fee schedule will need to transition members self-administering these products to a participating specialty pharmacy or an HTC already contracted with an HTC fee schedule when their current prior authorization expires.  

For more information, please contact your broker or UnitedHealthcare representative.